GlassScriptPhysician profile
Tammy M Kuron
NPI 1396185658
$5,805.18
in general payments reported to CMS, 2019-2025
32 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,236 · 2022: $833 · 2023: $1,231 · 2024: $1,182 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,736.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,320.90 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,116.14 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $591.75 | 2021-2025 | Korlym |
| Abbvie INC. | $241.30 | 2024-2025 | |
| Glaxosmithkline, LLC. | $216.49 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $207.54 | 2023-2025 | Symbravo, Auvelity |
| Sanofi-Aventis U.S. LLC | $190.12 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $187.65 | 2021 | |
| Bioventus LLC | $155.32 | 2025 | Exogen Ultrasound Bone Healing System, Durolane |
| Jazz Pharmaceuticals INC. | $125.00 | 2024 | |
| Argenx US, INC. | $124.56 | 2025 | Vyvgart |
| Neurocrine Biosciences, INC. | $117.35 | 2022 | |
| Pfizer INC. | $116.95 | 2023-2025 | |
| Sage Therapeutics, LLC | $111.92 | 2024 | |
| Inspire Medical Systems, INC. | $110.73 | 2024 | Inspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $90.69 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $86.37 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $84.76 | 2025 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $71.53 | 2025 | Voquezna |
| Biogen, INC. | $69.47 | 2023 | |
| Janssen Pharmaceuticals, INC | $66.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.34 | 2022-2023 | |
| Nevro Corp. | $49.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.81 | 2023-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $44.93 | 2024-2025 | |
| Lilly USA, LLC | $43.79 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $39.47 | 2024-2025 | Freestyle Libre 3 |
| Halozyme INC | $36.92 | 2023 | |
| Antares Pharma, INC. | $35.36 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $16.79 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $16.08 | 2023 | Evenity, Prolia |
| Astellas Pharma US INC | $13.19 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Kuron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.